We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of CL Wear Between Two Allergy Drops

This study has been withdrawn prior to enrollment.
(Protocol changes)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00489398
First Posted: June 21, 2007
Last Update Posted: October 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Hom, Milton M., OD, FAAO
June 19, 2007
June 21, 2007
October 7, 2010
July 2007
Not Provided
Contact lens objective and subjective clinical performance testing [ Time Frame: up to 3 months ]
Same as current
Complete list of historical versions of study NCT00489398 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparison of CL Wear Between Two Allergy Drops
Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride
Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
Contact lens patients will instill allergy drops and subjective and objective tests will be performed
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Allergic Conjunctivitis
Drug: epinastine HCL and olopatadine HCL
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
25
December 2008
Not Provided

Inclusion Criteria:

  • Males or females > 18 years old
  • Mild to moderate dry eye symptoms
  • Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

  • Current use of topical cyclosporine
  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable)
  • Ocular surgery within the past 3 months
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00489398
5316
Yes
Not Provided
Not Provided
Milton M. Hom, OD, FAAO.
Hom, Milton M., OD, FAAO
Merck Sharp & Dohme Corp.
Study Director: Milton M Hom, OD FAAO Private Practice
Hom, Milton M., OD, FAAO
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP